Biology and Genetics: The Role of RET and Hereditary Risk
At a Glance
Every patient diagnosed with Medullary Thyroid Carcinoma (MTC) must undergo blood testing for a RET gene mutation. This test determines whether the cancer is sporadic or hereditary, which is crucial for guiding your treatment plan and protecting your family members.
Understanding the biology of Medullary Thyroid Carcinoma (MTC) starts with a single gene: RET. This gene acts like a master switch for the growth of your C-cells. In healthy C-cells, the RET protein only sends a “grow” signal when it receives a specific instruction. However, in MTC, a mutation causes this switch to get stuck in the “on” position, leading to uncontrolled cell growth [1].
The Importance of Universal Genetic Testing
Current medical guidelines are clear: every single person diagnosed with MTC must undergo germline RET genetic testing [2][3]. This is a blood test that determines if the mutation is present in every cell of your body (hereditary) or only within the tumor itself (sporadic).
Even if you have no family history of thyroid issues, you still need this test. Roughly 25% of all MTC cases are hereditary, and sometimes a patient is the first person in their family to develop the mutation (a “de novo” mutation) [3]. Knowing your status is the only way to ensure your family members get the screening they may need.
Sporadic vs. Hereditary MTC
There are three main “categories” of MTC based on how the RET mutation occurs:
- Sporadic MTC (75% of cases): The mutation occurs by chance only in the thyroid cells. It cannot be passed down to children, and there is no increased risk for other types of tumors [4].
- MEN2A (Multiple Endocrine Neoplasia Type 2A): This is the most common hereditary form. In addition to MTC, patients have an increased risk of developing pheochromocytomas (adrenal gland tumors) and hyperparathyroidism (overactive parathyroid glands) [5][6].
- MEN2B (Multiple Endocrine Neoplasia Type 2B): This is a rarer and more aggressive hereditary form. It often appears very early in life and may include physical features like small bumps on the tongue (mucosal neuromas) or a tall, slender “marfanoid” body type [7].
Prophylactic Thyroidectomy: Protecting the Next Generation
One of the most powerful tools in managing hereditary MTC is the prophylactic thyroidectomy—removing the thyroid gland before cancer can even begin [8]. If a child is found to carry a RET mutation, the timing of their surgery is determined by the specific location of the mutation on the gene, as categorized by the American Thyroid Association (ATA) [9]:
- Highest Risk (MEN2B): Surgery is recommended as early as possible, often within the first year of life [10].
- High Risk: Surgery is typically recommended before the age of 5 [11].
- Moderate Risk: The timing is more flexible and is often guided by monitoring the child’s calcitonin levels [10].
The Role of Genetic Counseling
Receiving a genetic diagnosis can be emotionally taxing. A genetic counselor is a vital part of your care team. They help you interpret your results, explain the risks to your relatives, and provide psychosocial support for families navigating a shared health challenge. Furthermore, genetic counselors can help you navigate practical concerns, such as the implications of a genetic diagnosis on family planning or life insurance. Genetic counseling ensures that “cascade testing”—testing first-degree relatives like parents, siblings, and children—is done accurately and compassionately [12].
Common questions in this guide
Why do I need genetic testing if I have no family history of medullary thyroid cancer?
What is the difference between sporadic and hereditary MTC?
What are MEN2A and MEN2B syndromes?
What is a prophylactic thyroidectomy?
When should a child with a RET mutation have their thyroid removed?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my genetic testing, is my MTC sporadic or hereditary (germline)?
- 2.What is the specific codon mutation identified in my RET test, and how does it influence my risk or the risk for my family?
- 3.If a germline mutation is found, which family members (first-degree relatives) should be tested first?
- 4.Can you refer me to a genetic counselor who has experience with MEN2 syndromes?
- 5.For my children who test positive, what is their specific ATA risk category?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C, Ciampi R, Elisei R
Nature reviews. Endocrinology 2016; (12(4)):192-202 doi:10.1038/nrendo.2016.11.
PMID: 26868437 - 2
Histopathology of C Cells and Medullary Thyroid Carcinoma.
Cameselle-Teijeiro JM, Sobrinho-Simões M
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2025; (223()):9-50 doi:10.1007/978-3-031-80396-3_2.
PMID: 40102253 - 3
De novo mutation of the RET proto-oncogene revealing multiple endocrine neoplasia type 2A: a sporadic case from Western Algeria.
Chami A, Romanet P, Mohammedi F, et al.
The Gulf journal of oncology 2025; (1(49)):35-39.
PMID: 42272368 - 4
Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident.
Fisher SB, Cote GJ, Bui-Griffith JH, et al.
Surgery 2019; (165(1)):58-63 doi:10.1016/j.surg.2018.08.029.
PMID: 30392857 - 5
Medullary Thyroid Cancer: Epidemiology and Characteristics According to Data From the Marne-Ardennes Register 1975-2018.
Caillé S, Debreuve-Theresette A, Vitellius G, et al.
Journal of the Endocrine Society 2024; (8(6)):bvae084 doi:10.1210/jendso/bvae084.
PMID: 38745826 - 6
RET c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas
Zhao L, Yang KQ, Fan P, et al.
Genes 2022; (13(5)) doi:10.3390/genes13050864.
PMID: 35627249 - 7
Late-Onset Gastrointestinal Manifestations of Multiple Endocrine Neoplasia Type 2B (MEN2B): Diffuse Ganglioneuromatosis Causing Megacolon.
Rana M, Hussain S, Osman S, Anant P
Cureus 2025; (17(12)):e98366 doi:10.7759/cureus.98366.
PMID: 41487748 - 8
Untying the Next Genetic Thread in a Family With MEN2A Syndrome: A Case Report.
Shrestha R, Adil MA, Basnet B, et al.
Clinical case reports 2025; (13(10)):e71065 doi:10.1002/ccr3.71065.
PMID: 41079824 - 9
Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2.
Prete FP, Abdel-Aziz T, Morkane C, et al.
The British journal of surgery 2018; (105(10)):1319-1327 doi:10.1002/bjs.10856.
PMID: 29663329 - 10
Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study.
Zhang X, Yan D, Wang J, et al.
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2017; (29(3)):223-230 doi:10.21147/j.issn.1000-9604.2017.03.08.
PMID: 28729773 - 11
Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.
Castinetti F, Waguespack SG, Machens A, et al.
The lancet. Diabetes & endocrinology 2019; (7(3)):213-220 doi:10.1016/S2213-8587(18)30336-X.
PMID: 30660595 - 12
Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.
Milićević S, Bergant D, Žagar T, Perić B
Croatian medical journal 2021; (62(2)):110-119.
PMID: 33938650
This page provides educational information about RET gene mutations and hereditary risks associated with Medullary Thyroid Carcinoma. It does not replace professional medical advice. Always consult your oncologist or a certified genetic counselor to interpret your specific genetic testing results.
Get notified when new evidence is published on Medullary thyroid carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.